Literature DB >> 29633884

Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease.

Kinga G Blecharz-Lang1, Vincent Prinz2, Małgorzata Burek3, Dietmar Frey2, Tobias Schenkel1, Susanne M Krug4, Michael Fromm4, Peter Vajkoczy1,2,5.   

Abstract

Moyamoya disease (MMD) is a rare steno-occlusive cerebrovascular disorder. Mechanisms driving the formation of aberrant MMD vessels remain elusive. We collected serum and vessel specimens from MMD and atherosclerotic cerebrovascular disease (ACVD) patients serving as controls due to the same hypoxic stimulus but substantial differences in terms of vascular features. Based on patient material and an in vitro model mimicking ACVD and MMD conditions, matrix metalloproteinase-9 (MMP-9) and vascular-endothelial growth factor (VEGF) were tested for their potential involvement in cerebrovascular disintegration. While serum concentration of both molecules did not significantly differ in both patient groups, excessive collagenase activity and lowered collagen IV protein amount in MMD vessels pointed to a focal MMP-9 activity at the affected vessel sites. We observed overexpressed and autocrinely secreted MMP-9 and VEGF along with disturbances of EC-matrix interactions in MMD but not ACVD serum-treated cEND cells. These seemingly brain-specific effects were partially attenuated by VEGF signaling inhibition suggesting its role in the MMD etiology. In conclusion, our findings support the understanding of the high incidence of hemorrhagic and ischemic events in MMD and provide the basis for novel therapeutic strategies stopping or slowing the development of fragile cerebrovasculature or micro-bleeds characterizing the disease.

Entities:  

Keywords:  Moyamoya disease; angiogenesis; cytokine; endothelial cell; tight junction

Mesh:

Substances:

Year:  2018        PMID: 29633884      PMCID: PMC6259317          DOI: 10.1177/0271678X18768443

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  32 in total

Review 1.  Clinical applications of angiogenic growth factors and their inhibitors.

Authors:  N Ferrara; K Alitalo
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 3.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  Perfusion characteristics of Moyamoya disease: an anatomically and clinically oriented analysis and comparison.

Authors:  Gerrit Alexander Schubert; Marcus Czabanka; Marcel Seiz; Peter Horn; Peter Vajkoczy; Claudius Thomé
Journal:  Stroke       Date:  2013-11-05       Impact factor: 7.914

5.  Moyamoya disease: collateralization is everything.

Authors:  Peter Vajkoczy
Journal:  Cerebrovasc Dis       Date:  2009-07-14       Impact factor: 2.762

6.  Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions.

Authors:  Mira Lischper; Simon Beuck; Gokulan Thanabalasundaram; Christian Pieper; Hans-Joachim Galla
Journal:  Brain Res       Date:  2010-03-01       Impact factor: 3.252

7.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

8.  Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease.

Authors:  Miki Fujimura; Mika Watanabe; Ayumi Narisawa; Hiroaki Shimizu; Teiji Tominaga
Journal:  Surg Neurol       Date:  2009-01-14

9.  The effect of substrate modulus on the growth and function of matrix-embedded endothelial cells.

Authors:  Sylaja Murikipudi; Heiko Methe; Elazer R Edelman
Journal:  Biomaterials       Date:  2012-10-24       Impact factor: 12.479

10.  Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease.

Authors:  Kinga G Blecharz; Dietmar Frey; Tobias Schenkel; Vincent Prinz; Gloria Bedini; Susanne M Krug; Marcus Czabanka; Josephin Wagner; Michael Fromm; Anna Bersano; Peter Vajkoczy
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more
  10 in total

1.  Mutations of RNF213 are responsible for sporadic cerebral cavernous malformation and lead to a mulberry-like cluster in zebrafish.

Authors:  Jing Lin; Jie Liang; Jun Wen; Man Luo; Jiaoxing Li; Xunsha Sun; Xiaowei Xu; Jianli Li; Dongxian Wang; Jie Wang; Huimin Chen; Rong Lai; Fengyin Liang; Chuan Li; Fei Ye; Jingjing Zhang; Jinsheng Zeng; Shulan Yang; Wenli Sheng
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-04       Impact factor: 6.200

Review 2.  Pathological Circulating Factors in Moyamoya Disease.

Authors:  Yao-Ching Fang; Ling-Fei Wei; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

3.  Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells.

Authors:  Malgorzata Burek; Anna König; Mareike Lang; Jan Fiedler; Sabrina Oerter; Norbert Roewer; Michael Bohnert; Serge C Thal; Kinga G Blecharz-Lang; Johannes Woitzik; Thomas Thum; Carola Y Förster
Journal:  Transl Stroke Res       Date:  2019-01-08       Impact factor: 6.829

4.  Increased Catecholamine Levels and Inflammatory Mediators Alter Barrier Properties of Brain Microvascular Endothelial Cells in vitro.

Authors:  Cora Ittner; Malgorzata Burek; Stefan Störk; Michiaki Nagai; Carola Y Förster
Journal:  Front Cardiovasc Med       Date:  2020-05-05

5.  Analysis of microRNAs in Exosomes of Breast Cancer Patients in Search of Molecular Prognostic Factors in Brain Metastases.

Authors:  Carolin J Curtaz; Leonie Reifschläger; Linus Strähle; Jonas Feldheim; Julia J Feldheim; Constanze Schmitt; Matthias Kiesel; Saskia-Laureen Herbert; Achim Wöckel; Patrick Meybohm; Malgorzata Burek
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

Review 6.  Protocadherin gamma C3: a new player in regulating vascular barrier function.

Authors:  Victoria Kaupp; Kinga G Blecharz-Lang; Christina Dilling; Patrick Meybohm; Malgorzata Burek
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

7.  Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients.

Authors:  Jonas Feldheim; David Wend; Mara J Lauer; Camelia M Monoranu; Martin Glas; Christoph Kleinschnitz; Ralf-Ingo Ernestus; Barbara M Braunger; Patrick Meybohm; Carsten Hagemann; Malgorzata Burek
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

Review 8.  Circular RNAs and neutrophils: Key factors in tackling asymptomatic moyamoya disease.

Authors:  Sydney Corey; Yumin Luo
Journal:  Brain Circ       Date:  2019-09-30

9.  Plasma Lipid Profiling Contributes to Untangle the Complexity of Moyamoya Arteriopathy.

Authors:  Michele Dei Cas; Tatiana Carrozzini; Giuliana Pollaci; Antonella Potenza; Sara Nava; Isabella Canavero; Francesca Tinelli; Gemma Gorla; Ignazio G Vetrano; Francesco Acerbi; Paolo Ferroli; Elisa F Ciceri; Silvia Esposito; Veronica Saletti; Emilio Ciusani; Aida Zulueta; Rita Paroni; Eugenio A Parati; Riccardo Ghidoni; Anna Bersano; Laura Gatti
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

Review 10.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.